
## Young-Kee Shin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7610665/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer. Cancer Research and Treatment, 2023, 55, 145-154.	1.3	2
2	Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2–CCR2 signaling. Laboratory Investigation, 2022, 102, 376-390.	1.7	24
3	Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse. Pharmaceuticals, 2022, 15, 75.	1.7	11
4	A multipathogen DNA vaccine elicits protective immune responses against two class A bioterrorism agents, anthrax and botulism. Applied Microbiology and Biotechnology, 2022, 106, 1531-1542.	1.7	2
5	Visualization of a novel human monoclonal antibody against Claudin-3 for targeting ovarian cancer. Nuclear Medicine and Biology, 2022, 114-115, 135-142.	0.3	0
6	Ninjurin1 drives lung tumor formation and progression by potentiating Wnt/β-Catenin signaling through Frizzled2-LRP6 assembly. Journal of Experimental and Clinical Cancer Research, 2022, 41, 133.	3.5	6
7	SMAD4 Controls Cancer Cell Metabolism by Regulating Methylmalonic Aciduria Cobalamin Deficiency (cbl) B Type. Molecules and Cells, 2022, 45, 413-424.	1.0	2
8	A novel immune prognostic index for stratification of high-risk patients with early breast cancer. Scientific Reports, 2021, 11, 128.	1.6	5
9	TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis. Cancer Research and Treatment, 2021, 53, 9-24.	1.3	11
10	Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2â^ Early Breast Cancer. Frontiers in Oncology, 2021, 11, 588728.	1.3	2
11	Nuclear Respiratory Factor-1, a Novel SMAD4 Binding Protein, Represses TGF-β/SMAD4 Signaling by Functioning as a Transcriptional Cofactor. International Journal of Molecular Sciences, 2021, 22, 5595.	1.8	8
12	RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. Journal of Clinical Investigation, 2021, 131, .	3.9	23
13	Macrosphelide A Exhibits a Specific Anti-Cancer Effect by Simultaneously Inactivating ENO1, ALDOA, and FH. Pharmaceuticals, 2021, 14, 1060.	1.7	2
14	Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting. Biomolecules, 2020, 10, 51.	1.8	7
15	Molecular engineering of antibodies for site-specific conjugation to lipid polydopamine hybrid nanoparticles. Acta Pharmaceutica Sinica B, 2020, 10, 2212-2226.	5.7	21
16	Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses. Vaccines, 2020, 8, 403.	2.1	2
17	Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. Cancers, 2020, 12, 1575.	1.7	8
18	An Immune–Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood. Micromachines, 2020, 11, 560.	1.4	12

#	Article	IF	CITATIONS
19	Stability and Activity of the Hyperglycosylated Human Interferon-Î <sup>2</sup> R27T Variant. Scientific Reports, 2020, 10, 8412.	1.6	4
20	The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression. Cancer Research, 2020, 80, 2257-2272.	0.4	20
21	Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β). ACS Omega, 2020, 5, 6619-6627.	1.6	3
22	The ATF6-EGF Pathway Mediates the Awakening of Slow-Cycling Chemoresistant Cells and Tumor Recurrence by Stimulating Tumor Angiogenesis. Cancers, 2020, 12, 1772.	1.7	15
23	New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC. Pharmaceutics, 2020, 12, 121.	2.0	4
24	UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer. Frontiers in Oncology, 2020, 9, 1574.	1.3	27
25	Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing. Frontiers in Pharmacology, 2020, 11, 608774.	1.6	7
26	Abstract 4309: A novel immune prognostic index for the stratification of high-risk patients with early breast cancer. , 2020, , .		0
27	Immunogenicity and Biodistribution of Anthrax DNA Vaccine Delivered by Intradermal Electroporation. Current Drug Delivery, 2020, 17, 414-421.	0.8	2
28	Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. Frontiers in Oncology, 2019, 9, 667.	1.3	12
29	Phenotype-based discovery of a HeLa-specific cytotoxic molecule that downregulates HPV-mediated signaling pathwaysviaoxidative damage. Organic and Biomolecular Chemistry, 2019, 17, 7388-7397.	1.5	1
30	Dysregulation of miR-375/AEG-1 Axis by Human Papillomavirus 16/18-E6/E7 Promotes Cellular Proliferation, Migration, and Invasion in Cervical Cancer. Frontiers in Oncology, 2019, 9, 847.	1.3	30
31	Characterization and validation of somatic mutation spectrum to reveal heterogeneity in gastric cancer by single cell sequencing. Science Bulletin, 2019, 64, 236-244.	4.3	5
32	High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy. Breast Cancer Research, 2019, 21, 127.	2.2	16
33	Intradermal immunization with botulinum neurotoxin serotype E DNA vaccine induces humoral and cellular immunity and protects against lethal toxin challenge. Human Vaccines and Immunotherapeutics, 2019, 15, 412-419.	1.4	5
34	Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1. Journal of Microbiology and Biotechnology, 2019, 29, 1165-1176.	0.9	1
35	Abstract 1356: GENOCTC, a highly efficient system for enrichment of circulating tumor cells and its clinical application. , 2019, , .		Ο
36	Abstract LB-105: Therapeutic efficacy of ABN401, highly selective c-MET inhibitor, in NSCLC withMET-amplified AND/OREGFRmutation. , 2019, , .		0

#	Article	IF	CITATIONS
37	Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA. Scientific Reports, 2018, 8, 543.	1.6	16
38	Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells. Molecular Therapy - Nucleic Acids, 2018, 11, 455-467.	2.3	52
39	A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication. Human Vaccines and Immunotherapeutics, 2018, 14, 329-336.	1.4	4
40	MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells. Autophagy, 2018, 14, 812-824.	4.3	67
41	Cross-Protective Shigella Whole-Cell Vaccine With a Truncated O-Polysaccharide Chain. Frontiers in Microbiology, 2018, 9, 2609.	1.5	21
42	BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. PLoS ONE, 2018, 13, e0207155.	1.1	12
43	Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. Cellular Physiology and Biochemistry, 2018, 51, 2647-2693.	1.1	206
44	Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients. Scientific Reports, 2018, 8, 18064.	1.6	13
45	Physostigmine-loaded liposomes for extended prophylaxis against nerve agent poisoning. International Journal of Pharmaceutics, 2018, 553, 467-473.	2.6	9
46	A Glycoengineered Interferon-β Mutein (R27T) Generates Prolonged Signaling by an Altered Receptor-Binding Kinetics. Frontiers in Pharmacology, 2018, 9, 1568.	1.6	6
47	Upregulation of SMAD4 by MZF1 inhibits migration of human gastric cancer cells. International Journal of Oncology, 2017, 50, 272-282.	1.4	13
48	A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2â^' early breast cancer. Scientific Reports, 2017, 7, 45554.	1.6	26
49	MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer Research and Treatment, 2017, 164, 41-56.	1.1	51
50	Intestinal Epithelial Cell-Specific Deletion of PLD2 Alleviates DSS-Induced Colitis by Regulating Occludin. Scientific Reports, 2017, 7, 1573.	1.6	25
51	MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. Journal of Thoracic Oncology, 2017, 12, 1233-1246.	0.5	68
52	A novel staphylococcal enterotoxin B subunit vaccine candidate elicits protective immune response in a mouse model. Toxicon, 2017, 131, 68-77.	0.8	12
53	Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer. Pathology, 2017, 49, 618-626.	0.3	14
54	Polyamidoamine-Decorated Nanodiamonds as a Hybrid Gene Delivery Vector and siRNA Structural Characterization at the Charged Interfaces. ACS Applied Materials & Interfaces, 2017, 9, 31543-31556.	4.0	48

#	Article	IF	CITATIONS
55	Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. Clinical Cancer Research, 2017, 23, 1299-1311.	3.2	24
56	ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cellsThis article has been corrected since Advance Online Publication and an erratum is also printed in this issue. Oncogenesis, 2017, 6, e389-e389.	2.1	56
57	Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation of TP53/E2F Dynamic Behavior for Cell Fate Decisions. Neoplasia, 2017, 19, 735-749.	2.3	14
58	Enhanced Cell Growth of Adipocyte-Derived Mesenchymal Stem Cells Using Chemically-Defined Serum-Free Media. International Journal of Molecular Sciences, 2017, 18, 1779.	1.8	37
59	Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. Oncotarget, 2017, 8, 61538-61550.	0.8	28
60	Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans. PLoS ONE, 2017, 12, e0185826.	1.1	10
61	Sensitization of glycoengineered interferon-β1a-resistant cancer cells by cFLIP inhibition for enhanced anti-cancer therapy. Oncotarget, 2017, 8, 13957-13970.	0.8	5
62	Genes co-amplified with <i>ERBB2</i> or <i>MET</i> as novel potential cancer-promoting genes in gastric cancer. Oncotarget, 2017, 8, 92209-92226.	0.8	26
63	Abstract LB-241: Quantification of EGFR allele frequency predicts tumor response to EGFR tyrosine kinase inhibitors. , 2017, , .		0
64	Identification of diagnostic biomarkers for early detection of anthrax from human aortic endothelial cells. International Journal of Nanotechnology, 2016, 13, 413.	0.1	0
65	Efficiency of methylated DNA immunoprecipitation bisulphite sequencing for whole-genome DNA methylation analysis. Epigenomics, 2016, 8, 1061-1077.	1.0	11
66	The potential role of PHF6 as an oncogene: a genotranscriptomic/proteomic meta-analysis. Tumor Biology, 2016, 37, 5317-5325.	0.8	9
67	Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea. PLoS ONE, 2016, 11, e0160155.	1.1	12
68	LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients. Oncotarget, 2016, 7, 82876-82888.	0.8	11
69	Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines. Journal of Visualized Experiments, 2015, , .	0.2	2
70	Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. Journal of Clinical Medicine, 2015, 4, 1126-1155.	1.0	33
71	Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. International Journal of Molecular Sciences, 2015, 16, 12243-12260.	1.8	19
72	Transducer of ERBB2.1 (TOB1) as a Tumor Suppressor: A Mechanistic Perspective. International Journal of Molecular Sciences, 2015, 16, 29815-29828.	1.8	26

#	Article	IF	CITATIONS
73	CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer. PLoS ONE, 2015, 10, e0139112.	1.1	78
74	Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples. PLoS ONE, 2015, 10, e0144162.	1.1	76
75	Basal buffer systems for a newly glycosylated recombinant human interferon-β with biophysical stability and DoE approaches. European Journal of Pharmaceutical Sciences, 2015, 78, 177-189.	1.9	6
76	Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9722-9727.	3.3	53
77	STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody. Nature Communications, 2015, 6, 8499.	5.8	34
78	Abstract 2115: Effect of small interfering RNA targeting HPV E6/E7 gene on the regulation of TP53/Rb dynamic behaviour in cervical cancer cells. , 2015, , .		0
79	Glycoengineering of Interferon-Î <sup>2</sup> 1a Improves Its Biophysical and Pharmacokinetic Properties. PLoS ONE, 2014, 9, e96967.	1.1	30
80	Development of an Advanced Synthetic Route to Macrosphelides and Its Application to the Discovery of a More Potent Macrosphelide Derivative. Molecules, 2014, 19, 15572-15583.	1.7	2
81	SMAD4 Suppresses AURKA-Induced Metastatic Phenotypes via Degradation of AURKA in a TGFβ-Independent Manner. Molecular Cancer Research, 2014, 12, 1779-1795.	1.5	20
82	Overexpression of Cancer-Associated Genes via Epigenetic Derepression Mechanisms in Gynecologic Cancer. Frontiers in Oncology, 2014, 4, 12.	1.3	27
83	MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. International Journal of Cancer, 2014, 134, 2424-2436.	2.3	75
84	Molecular function and regulation of long non-coding RNAs: paradigms with potential roles in cancer. Tumor Biology, 2014, 35, 10645-10663.	0.8	48
85	Design and synthesis of a macrosphelide A-biotin chimera. Organic and Biomolecular Chemistry, 2014, 12, 7127.	1.5	6
86	Abstract 5171: An integrated analysis of copy number alteration and global gene expression reveals potential oncogenes underlying stomach cancer. , 2014, , .		3
87	Abstract 4180: Clonal evolution of tumor cell population in a patient with repetitively recurrent dermatofibrosarcoma protuberance (DFSP). , 2014, , .		0
88	Abstract 2785: LYN is a new prognostic and therapeutic target in non-small cell lung cancer. , 2014, , .		0
89	High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. Histology and Histopathology, 2014, 29, 127-38.	0.5	30
90	Human aortic endothelial cells compare favourably with macrophages for the study of anthrax toxins. International Journal of Nanotechnology, 2013, 10, 756.	0.1	0

#	Article	IF	CITATIONS
91	CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype. Biochemical and Biophysical Research Communications, 2013, 432, 333-338.	1.0	30
92	Prognostic significance of CD151 overexpression in non-small cell lung cancer. Lung Cancer, 2013, 81, 109-116.	0.9	25
93	Synthesis and Biological Evaluation of a Polyyne-Containing Sphingoid Base Probe as a Chemical Tool. Bioconjugate Chemistry, 2013, 24, 1324-1331.	1.8	20
94	Regulation of Ovarian Cancer Stem Cells or Tumor-Initiating Cells. International Journal of Molecular Sciences, 2013, 14, 6624-6648.	1.8	59
95	Low SP1 Expression Differentially Affects Intestinal-Type Compared with Diffuse-Type Gastric Adenocarcinoma. PLoS ONE, 2013, 8, e55522.	1.1	19
96	Long non-coding RNAs in hematologic malignancies: road to translational research. Frontiers in Genetics, 2013, 4, 250.	1.1	14
97	Abstract 4391: MET is a potential therapeutic target and a candidate for combination therapy with ECFR inhibition in triple-negative/basal-like breast cancer , 2013, , .		0
98	Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. British Journal of Cancer, 2012, 106, 923-930.	2.9	57
99	Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting β-catenin signaling. International Journal of Oncology, 2012, 41, 839-848.	1.4	51
100	Epigenetic control of metastasis-associated protein 1 gene expression by hepatitis B virus X protein during hepatocarcinogenesis. Oncogenesis, 2012, 1, e25-e25.	2.1	16
101	A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. Breast Cancer Research and Treatment, 2012, 132, 499-509.	1.1	19
102	The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines <i>in vitro</i> and <i>in vivo</i> . International Journal of Cancer, 2012, 130, 1925-1936.	2.3	33
103	High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histology and Histopathology, 2012, 27, 197-207.	0.5	130
104	Abstract LB-155: Smad4 negatively regulates beta-catenin signaling through proteasomal degradation of Aurora A in human cancer cells. , 2012, , .		0
105	Epigenetic Regulation of Cancer-Associated Genes in Ovarian Cancer. International Journal of Molecular Sciences, 2011, 12, 983-1008.	1.8	65
106	Cancer-Associated Splicing Variant of Tumor Suppressor AIMP2/p38: Pathological Implication in Tumorigenesis. PLoS Genetics, 2011, 7, e1001351.	1.5	84
107	The potential RNAi-based combination therapeutics. Archives of Pharmacal Research, 2011, 34, 1-2.	2.7	7
108	Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma. Laboratory Investigation, 2011, 91, 1652-1667.	1.7	73

#	Article	IF	CITATIONS
109	Abstract LB-112: SP1 suppression is associated with poor prognosis in intestinal-type gastric adenocarcinoma. , 2011, , .		1
110	Abstract 2177: A novel protein interaction between Smad4 and NRF1 establishes a molecular switch on p15Ink4bexpression. , 2011, , .		0
111	Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer, 2010, 10, 507.	1.1	46
112	LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer. Cancer Research, 2010, 70, 2296-2306.	0.4	128
113	Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis, 2010, 31, 974-983.	1.3	69
114	Merkel cell carcinoma: Our experience with seven patients in Korea and a literature review. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2010, 63, 2064-2070.	0.5	22
115	The Transcription Factor MIST1 Is a Novel Human Gastric Chief Cell Marker Whose Expression Is Lost in Metaplasia, Dysplasia, and Carcinoma. American Journal of Pathology, 2010, 177, 1514-1533.	1.9	105
116	A case of Hyper-IgE syndrome with a mutation of the STAT3 gene. Korean Journal of Pediatrics, 2010, 53, 592.	1.9	1
117	Identification of Novel Reference Genes Using Multiplatform Expression Data and Their Validation for Quantitative Gene Expression Analysis. PLoS ONE, 2009, 4, e6162.	1.1	103
118	Resveratrol Suppresses Growth of Human Ovarian Cancer Cells in Culture and in a Murine Xenograft Model: Eukaryotic Elongation Factor 1A2 as a Potential Target. Cancer Research, 2009, 69, 7449-7458.	0.4	69
119	Honokiol reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes. Toxicology and Applied Pharmacology, 2009, 236, 124-130.	1.3	44
120	Expression of Sonic hedgehog signaling molecules in normal, hyperplastic and carcinomatous endometrium. Pathology International, 2009, 59, 279-287.	0.6	26
121	Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology, 2009, 49, 1122-1131.	3.6	135
122	Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Research and Treatment, 2009, 113, 83-93.	1.1	46
123	Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-κB and C/EBP as potential targets. Cancer Letters, 2009, 273, 86-97.	3.2	31
124	A novel mutation in the linker domain of the signal transducer and activator of transcription 3 gene, p.Lys531Glu, in hyper-IgE syndrome. Journal of Allergy and Clinical Immunology, 2009, 123, 956-958.	1.5	19
125	Magnolia officinalis Reverses Alcoholic Fatty Liver by Inhibiting the Maturation of Sterol Regulatory Element–Binding Protein-1c. Journal of Pharmacological Sciences, 2009, 109, 486-495.	1.1	31
126	Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histology and Histopathology, 2009, 24, 309-16.	0.5	14

#	Article	IF	CITATIONS
127	The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clinical Rheumatology, 2008, 27, 437-442.	1.0	21
128	Identification of formaldehyde-responsive genes by suppression subtractive hybridization. Toxicology, 2008, 243, 224-235.	2.0	8
129	TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature, 2008, 455, 1210-1215.	13.7	1,144
130	Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene, 2008, 27, 3405-3413.	2.6	147
131	Involvement of Promyelocytic Leukemia Protein in the Ethanol-induced Apoptosis in Mouse Embryo Fibroblasts. Yakugaku Zasshi, 2008, 128, 1067-1071.	0.0	4
132	Extensive alteration in the expression profiles of TGFB pathway signaling components and TP53 is observed along the gastric dysplasia-carcinoma sequence. Histology and Histopathology, 2008, 23, 1439-52.	0.5	13
133	Inactivation of SMAD4 Tumor Suppressor Gene During Gastric Carcinoma Progression. Clinical Cancer Research, 2007, 13, 102-110.	3.2	92
134	Clinical Significance of CD99 Down-Regulation in Gastric Adenocarcinoma. Clinical Cancer Research, 2007, 13, 2584-2591.	3.2	28
135	Overexpression of Interleukin-10 in Sentinel Lymph Node with Breast Cancer. Annals of Surgical Oncology, 2007, 14, 3268-3273.	0.7	7
136	Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histology and Histopathology, 2007, 22, 1185-95.	0.5	65
137	Overexpression of CD24: Association With Invasiveness in Urothelial Carcinoma of the Bladder. Archives of Pathology and Laboratory Medicine, 2007, 131, 275-281.	1.2	26
138	Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions. Modern Pathology, 2006, 19, 675-683.	2.9	87
139	Enhanced expression of hedgehog signaling molecules in squamous cell carcinoma of uterine cervix and its precursor lesions. Modern Pathology, 2006, 19, 1139-1147.	2.9	50
140	Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 331-336.	1.4	41
141	Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-IºB and AP-1 as prime targets. Biochemical Pharmacology, 2006, 72, 1506-1515.	2.0	190
142	Combining multiple microarrays in the presence of controlling variables. Bioinformatics, 2006, 22, 1682-1689.	1.8	37
143	Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity. Carcinogenesis, 2006, 27, 1465-1474.	1.3	248
144	TRPV1 Recapitulates Native Capsaicin Receptor in Sensory Neurons in Association with Fas-Associated Factor 1. Journal of Neuroscience, 2006, 26, 2403-2412.	1.7	53

#	Article	IF	CITATIONS
145	[6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-κB in phorbol ester-stimulated mouse skin. Oncogene, 2005, 24, 2558-2567.	2.6	267
146	Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecologic Oncology, 2005, 97, 379-386.	0.6	59
147	HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. Journal of Neuro-Oncology, 2005, 73, 19-27.	1.4	7
148	From The Cover: Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6356-6361.	3.3	155
149	Rapid divergency of rodent CD99 orthologs: Implications for the evolution of the pseudoautosomal region. Gene, 2005, 353, 177-188.	1.0	35
150	The Haploinsufficient Tumor Suppressor p18 Upregulates p53 via Interactions with ATM/ATR. Cell, 2005, 120, 209-221.	13.5	126
151	The Novel Cytokine p43 Stimulates Dermal Fibroblast Proliferation and Wound Repair. American Journal of Pathology, 2005, 166, 387-398.	1.9	113
152	An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. Histology and Histopathology, 2005, 20, 59-66.	0.5	22
153	An Immunohistochemical Study of the Expression of Adhesion Molecules in Gallbladder Lesions. Journal of Histochemistry and Cytochemistry, 2004, 52, 591-601.	1.3	46
154	Evaluation of Antigen Retrieval Buffer Systems. Journal of Molecular Histology, 2003, 35, 409-416.	1.0	43
155	Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications. Cancer Immunology, Immunotherapy, 2003, 52, 506-512.	2.0	16
156	Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2 , a novel paralog of human CD99, and identification of evolutionary conserved motifs. Gene, 2003, 307, 63-76.	1.0	53
157	An Improved Protocol of Biotinylated Tyramine-based Immunohistochemistry Minimizing Nonspecific Background Staining. Journal of Histochemistry and Cytochemistry, 2003, 51, 129-132.	1.3	32
158	Identification of antigenic peptide recognized by the anti-JL1 leukemia-specific monoclonal antibody from combinatorial peptide phage display libraries. Journal of Cancer Research and Clinical Oncology, 2002, 128, 641-649.	1.2	10
159	The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramine. The Histochemical Journal, 2002, 34, 97-103.	0.6	29
160	Mutations of the immunoglobulin heavy chain variable region gene in CD99-deficient BJAB cell line. Molecules and Cells, 2002, 13, 237-44.	1.0	2
161	Expression of Leukemia-Associated Antigen, JL1, in Bone Marrow and Thymus. American Journal of Pathology, 2001, 158, 1473-1480.	1.9	12
162	LMP1-Induced Downregulation of CD99 Molecules in Hodgkin and Reed-Sternberg Cells. Leukemia and Lymphoma, 2001, 42, 587-594.	0.6	14

#	Article	IF	CITATIONS
163	CD99 Regulates the Transport of MHC Class I Molecules from the Golgi Complex to the Cell Surface. Journal of Immunology, 2001, 166, 787-794.	0.4	56
164	Immature thymocyte antigen, JL1, as a possible immunodiagnostic and immunotherapeutic target for leukemia. Immune Network, 2001, 1, 1.	1.6	0
165	Viral latent membrane protein 1 (LMP-1)–induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood, 2000, 95, 294-300.	0.6	69
166	High CD99 expression in memory T and B cells in reactive lymph nodes. Journal of Korean Medical Science, 1999, 14, 600.	1.1	33
167	Reduced expression of CD99 and functional disturbance in anencephalic cortical thymocytes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1999, 434, 443-449.	1.4	14
168	Generation of Cells With Hodgkin's and Reed-Sternberg Phenotype Through Downregulation of CD99 (Mic2). Blood, 1998, 92, 4287-4295.	0.6	57
169	Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. Frontiers in Oncology, 0, 12	1.3	22